Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioRestorative Therapies (BRTX) Research & Development (2016 - 2025)

Historic Research & Development for BioRestorative Therapies (BRTX) over the last 15 years, with Q3 2025 value amounting to $2.6 million.

  • BioRestorative Therapies' Research & Development rose 7853.42% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year increase of 3606.38%. This contributed to the annual value of $5.3 million for FY2024, which is 3257.13% up from last year.
  • As of Q3 2025, BioRestorative Therapies' Research & Development stood at $2.6 million, which was up 7853.42% from $2.2 million recorded in Q2 2025.
  • In the past 5 years, BioRestorative Therapies' Research & Development ranged from a high of $2.6 million in Q3 2025 and a low of $160898.0 during Q2 2021
  • For the 5-year period, BioRestorative Therapies' Research & Development averaged around $1.0 million, with its median value being $989170.0 (2022).
  • Its Research & Development has fluctuated over the past 5 years, first surged by 56826.44% in 2022, then plummeted by 6845.2% in 2024.
  • Over the past 5 years, BioRestorative Therapies' Research & Development (Quarter) stood at $165496.0 in 2021, then surged by 307.03% to $673621.0 in 2022, then soared by 61.83% to $1.1 million in 2023, then crashed by 68.45% to $343915.0 in 2024, then surged by 654.47% to $2.6 million in 2025.
  • Its Research & Development stands at $2.6 million for Q3 2025, versus $2.2 million for Q2 2025 and $1.7 million for Q1 2025.